TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03614923

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Etokimab
Description: Administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone Furoate Nasal Spray
Description: Mometasone Furoate Nasal Spray (MFNS) was used from 4 weeks prior to Day 1 (Run-in period) through the end of the study. Participants used 2 actuations (50 μg/actuation) in each nostril BID, total daily dose of 400 μg. Participants intolerant to BID intranasal corticosteroids (INCS) could use the lower dose regimen of 1 actuation in each nostril BID, total daily dose of 200 μg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone Furoate Nasal Spray
Description: Mometasone Furoate Nasal Spray (MFNS) was used from 4 weeks prior to Day 1 (Run-in period) through the end of the study. Participants used 2 actuations (50 μg/actuation) in each nostril BID, total daily dose of 400 μg. Participants intolerant to BID intranasal corticosteroids (INCS) could use the lower dose regimen of 1 actuation in each nostril BID, total daily dose of 200 μg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mometasone Furoate Nasal Spray
Description: Mometasone Furoate Nasal Spray (MFNS) was used from 4 weeks prior to Day 1 (Run-in period) through the end of the study. Participants used 2 actuations (50 μg/actuation) in each nostril BID, total daily dose of 400 μg. Participants intolerant to BID intranasal corticosteroids (INCS) could use the lower dose regimen of 1 actuation in each nostril BID, total daily dose of 200 μg.
Study: NCT04457245

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo whole body PET/CT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluorine F 18 DCFPyL
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo whole body PET/CT

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Undergo standard of care definitive radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo standard of care definitive radiation therapy
Study: NCT01545271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: xenon gas
Description: Inhalation via endotracheal tube of 50% xenon for 18 hours, including during transport for outborn babies, starting within 5 hours after birth.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole body cooling
Description: Cooling of baby to reduce rectal temperature to 33.5 degree Centigrade(standard treatment), including during transport for outborn babies, starting within 3 hours after birth.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Whole body cooling
Description: Cooling of baby to reduce rectal temperature to 33.5 degree Centigrade(standard treatment), including during transport for outborn babies, starting within 3 hours after birth.
Study: NCT00082784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alvocidib Hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT03606759

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Weekly assessment
Description: Weekly assessment during 3 months :~Severity of addiction (Addiction Severity Index, ASI) Mini International Neuropsychiatric Interview, MINI Craving intensity (BILAN-7 jours) Individual cues of each participant (QSA) Substance use and gambling (BILAN-7 jours)
Study: NCT02725671

Intervention type: DEVICE
Group type: OTHER
Intervention: Explorer
Description: ECG device which records comprehensive voltage potential data in the myocardium
Study: NCT03473834

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified exercise programme
Description: The exercise will be modified from the standardized exercise program (Schenkman, 1998) includes a series of exercises based on the concept that muscle length and coordination.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication
Description: The control group will be received the normal medication from their doctor.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Medication
Description: The control group will be received the normal medication from their doctor.
Study: NCT01965535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: LDV/SOF (90/400 mg) FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: LDV/SOF (90/400 mg) FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: RBV (200 mg tablets) administered orally in a divided daily dose based on weight (1000 mg per day for participants weighing \< 75 kg; 1200 mg per day for participants weighing ≥ 75 kg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match LDV/SOF
Description: Placebo to match LDV/SOF administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match RBV
Description: Placebo to match RBV administered orally in a divided daily dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match RBV
Description: Placebo to match RBV administered orally in a divided daily dose
Study: NCT02491866

Intervention type: OTHER
Group type: OTHER
Intervention: to develop and validate a Computerized Adaptative Testing
Description: * Elaboration of a pool of items, based on literature review and interview with patients.~* Selection of the most relevant items based on a qualitative approach using cognitive interview with patients.~* Calibration of the item bank : the psychometric properties of the item bank will be based on classical test and item response theories and approaches, including the evaluation of unidimensionality, item response theory model fitting, and analyses of differential item functioning.~* Metrological validation of the CAT.~* Analysis of the implementation of the CAT in clinical practice using interview with professionals and patients.
Study: NCT02221336

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The MONARCA II system
Description: Daily electronic monitoring of subjective and objective smartphone measures including a feedback loop

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Non-MONARCA II system
Description: Daily use of smartphone for normal communicative purposes. No self-monitoring in the MONARCA II system.
Study: NCT01669122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine
Description: 4 mg nicotine lozenge experimental

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine
Description: 4 mg nicotine lozenge experimental

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nicotine
Description: 4 mg nicotine lozenge experimental
Study: NCT03451838

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Ultrasound will be done to every pregnant lady

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Ultrasound will be done to every pregnant lady

Intervention type: DIAGNOSTIC_TEST
Intervention: HbA1c level in blood
Description: a blood sample will be taken to measure HbA1c level

Intervention type: DIAGNOSTIC_TEST
Intervention: HbA1c level in blood
Description: a blood sample will be taken to measure HbA1c level
Study: NCT04331366

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GO2 PEEP MOUTHPIECE
Description: The GO2 PEEP MOUTHPIECE has a bidirectional valve that delivers PEEP with each breath. Participants will be provided a G02 PEEP MOUTHPIECE to use underneath the oxygen face mask and will be instructed to breathe slowly and deeply through the mouthpiece for 15 minutes total. Metrics for primary and secondary endpoints will be recorded immediately prior to use and then at 5, 10 and 15 minutes of use and then 15 minutes after cessation of use.
Study: NCT01703455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: 400 mg twice daily, on a continuous basis (each morning and evening), in 4 week cycles
Study: NCT00275093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temsirolimus
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT02959060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986177
Description: Single dose of BMS-986177 and multiple doses of Rifampin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Single dose of BMS-986177 and multiple doses of Rifampin
Study: NCT01404312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifapentine (RPT)
Description: RPT dosing was be based on participants' weight:~Participants who weighed 30 kg to less than 35 kg received 300 mg once daily (administered as two 150-mg tablets).~Participants who weighed 35 kg to less than 45 kg received 450 mg once daily (administered as three 150-mg tablets).~Participants who weighed greater than 45 kg received 600 mg once daily (administered as four 150-mg tablets).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid (INH)
Description: Participants received one 300-mg tablet or three 100-mg tablets of INH once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid (INH)
Description: Participants received one 300-mg tablet or three 100-mg tablets of INH once daily.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pyridoxine (Vitamin B6)
Description: Participants received 25 mg or 50 mg of pyridoxine, based on the current local, national, or international dosing guidelines.~Participants who received 25 mg of pyridoxine took one 25-mg tablet once daily with INH.~Participants who received 50 mg of pyridoxine took two 25-mg tablets once daily with INH.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pyridoxine (Vitamin B6)
Description: Participants received 25 mg or 50 mg of pyridoxine, based on the current local, national, or international dosing guidelines.~Participants who received 25 mg of pyridoxine took one 25-mg tablet once daily with INH.~Participants who received 50 mg of pyridoxine took two 25-mg tablets once daily with INH.
Study: NCT04000451

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: oxyhydrogen
Description: Hydrogen/oxygen mixed gas inhaled(proportion 2:1),3 L/min . 1 hour each time,twice a day(BID).Test Duration is seven days

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: oxygen inhaled,3 L/min . 1 hour each time,twice a day(BID).Test Duration is seven days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional treatment
Description: Bronchodilator (LABA,LAMA) with or without ICS.Conventional treatment is invariable with which was given to COPD patients in seven days before the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional treatment
Description: Bronchodilator (LABA,LAMA) with or without ICS.Conventional treatment is invariable with which was given to COPD patients in seven days before the study
Study: NCT01097135

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duraprep Surgical Solution
Study: NCT04477980

Intervention type: OTHER
Intervention: Disease outcome (mortality)
Description: Mortality rate between the two groups

Intervention type: OTHER
Intervention: Disease outcome (mortality)
Description: Mortality rate between the two groups
Study: NCT00158379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 4 cycles of Carboplatin AUC 5 every 3 weeks. 12 weekly infusions of 80 mg/m² Taxol®
Study: NCT01868581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Each subject will be allocated to 2 single injections of trial product on 2 separate dosing visits, administered subcutaneously (s.c., under the skin).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart
Description: Each subject will be allocated to 2 single injections of trial product on 2 separate dosing visits, administered subcutaneously (s.c., under the skin).
Study: NCT04514315

Intervention type: PROCEDURE
Intervention: Minimally invasive cardiac valvular surgery
Description: Minimally invasive valve surgery via right mini-thoracotomy.

Intervention type: PROCEDURE
Intervention: Minimally invasive cardiac valvular surgery
Description: Minimally invasive valve surgery via right mini-thoracotomy.

Intervention type: PROCEDURE
Intervention: Conventional cardiac valvular surgery
Description: Conventional valve surgery via full median sternotomy
Study: NCT05684016

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NeuroQuant
Description: Reliably defines the volume of those parts of the brain that are important for memory and thinking.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NeuroQuant
Description: Reliably defines the volume of those parts of the brain that are important for memory and thinking.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NeuroQuant
Description: Reliably defines the volume of those parts of the brain that are important for memory and thinking.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Automated Neuropsychological Assessment Matrices
Description: This is like an IQ test.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Automated Neuropsychological Assessment Matrices
Description: This is like an IQ test.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EDSS
Description: Extended Disability Status Score

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EDSS
Description: Extended Disability Status Score

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Examination
Description: Physical Examination

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Examination
Description: Physical Examination
Study: NCT01230593

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hot Compress plus Tobramycin Drops and Ointment
Description: In addition to hot compress, Tobramycin drops will be given to the affected eye 3x/day, and Tobramycin ointment will be given at night before bed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hot compress plus Tobramycin/Dexamethasone Drops and Ointment
Description: In addition to hot compress, Tobramycin/Dexamethasone drops will be given to the affected eye 3x/day, and Tobramycin/Dexamethasone ointment will be given at night before bed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hot Compresses
Description: Hot compresses 3x/day to eyelids
Study: NCT03809182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: A bolus of 1ug/kg in 10 minutes, followed by an infusion of 0.5ug/kg/h until the end of surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium-chloride
Description: The same infusion rate used in the dexmedetomidine group.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fentanyl
Description: Intraoperative fentanyl was given in case of 25% increment in the blood pressure and/or heart rate in comparison to baseline (previous anesthesia induction).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Intraoperative fentanyl was given in case of 25% increment in the blood pressure and/or heart rate in comparison to baseline (previous anesthesia induction).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine Sulfate
Description: Boluses of 3mg of intravenous morphine were given in the postoperative acute care unit. Once the pain score was equal or less than 3/10 the patient-controlled analgesia pumps were installed and the patients were discharged to their room.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine Sulfate
Description: Boluses of 3mg of intravenous morphine were given in the postoperative acute care unit. Once the pain score was equal or less than 3/10 the patient-controlled analgesia pumps were installed and the patients were discharged to their room.
Study: NCT01169870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genexol-PM
Description: Treatment is given in the outpatient setting. Patients receive treatment every 3 weeks up to 6 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Study: NCT04015648

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1 Zika
Description: Single dose of ChAdOx1 Zika at different concentrations: 5 x 10\^9 vp, 2.5 x 10\^10 vp, 5 x 10\^10 vp

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1 Zika
Description: Single dose of ChAdOx1 Zika at different concentrations: 5 x 10\^9 vp, 2.5 x 10\^10 vp, 5 x 10\^10 vp

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1 Zika
Description: Single dose of ChAdOx1 Zika at different concentrations: 5 x 10\^9 vp, 2.5 x 10\^10 vp, 5 x 10\^10 vp
Study: NCT00903591

Intervention type: OTHER
Intervention: questionaire, blood or saliva sample
Description: Take part in an approximately 45 minute telephone interview, with questions about detailed treatment (chemotherapy, hormonal therapy, radiation therapy (RT)) for all study participants. Their medical records will be reviewed to get further details about treatment of their breast cancer. They donate either a 35 ml blood sample (about 3 tablespoons) or a saliva sample. Blood Sample: if patient consents to give a blood sample, following the interview, they will be contacted by our staff phlebotomist (a person trained to draw blood). A scheduled appointment to draw a blood sample from you at your home. At the time of the blood draw, the phlebotomist will collect approximately 2 and 1/3 tablespoons of blood. Saliva Sample: if they choose not to give a blood sample, but consent to give a saliva sample instead, a saliva kit will be sent to there home. Once they provide the sample in the kit, they will be asked to mail back the sample in the pre-labeled kit that was sent to them.
Study: NCT02527616

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FFR Infusion Microcatheter and standard intra-venous (IV) infusion
Description: Cross-over design where FFR is measured twice in the same lesion using standard standard intra-venous (IV) infusion and new method

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FFR Infusion Microcatheter and standard intra-venous (IV) infusion
Description: Cross-over design where FFR is measured twice in the same lesion using standard standard intra-venous (IV) infusion and new method
Study: NCT02622503

Intervention type: DRUG
Intervention: Rituximab
Description: This is an observational study. Patients with rheumatoid arthritis and having received treatment previously will be assessed for the treatment responses.
Study: NCT02008331

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SYNBIOTIC
Description: INTERVENTION: Probinul neutro® assumed three times a day far from meals as 5 g powder packets dissolved in water. Probinul neutro® contains 5×109 Lactobacillus plantarum, 2×109 Lactobacillus casei subp. rhamnosus and 2×109 Lactobacillus gasseri, 1×109 Bifidobacterium infantis and 1×109 Bifidobacterium longum, 1×109 Lactobacillus acidophilus, 1×109 Lactobacillus salivarus and 1×109 Lactobacillus sporogenes and 5×109 Streptococcus termophilus, prebiotic inulin (2.2 g; VB Beneo Synergy 1) and 1.3 g of tapioca-resistant starch.~PLACEBO: Tapioca-resistant starch powder similar in colour, texture and taste to the symbiotic mixture, assumed three times a day far from meals as 5 g powder packets dissolved in water.
Study: NCT02529085

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood samples
Description: blood samples for the bank

Intervention type: OTHER
Group type: OTHER
Intervention: blood samples
Description: blood samples for the bank
Study: NCT01952639

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: protein type and amount
Description: Subjects will stay in a supine position and consume a test beverage containing different amounts ans types of protein

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: protein type and amount
Description: Subjects will stay in a supine position and consume a test beverage containing different amounts ans types of protein

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: protein type and amount
Description: Subjects will stay in a supine position and consume a test beverage containing different amounts ans types of protein

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: protein type and amount
Description: Subjects will stay in a supine position and consume a test beverage containing different amounts ans types of protein

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: protein type and amount
Description: Subjects will stay in a supine position and consume a test beverage containing different amounts ans types of protein
Study: NCT02405715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray or placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxytocin nasal spray or placebo
Study: NCT03873649

Intervention type: OTHER
Intervention: Bronchoscopy with lavage
Description: Bronchoscopy will be performed according to standard clinical procedures. Bronchoscopy will be performed under conscious sedation with continuous cardiopulmonary monitoring and the subject's upper airway will be anesthetized with topical lidocaine. The bronchoscope will be passed through the naris or mouth to the upper airway and then into the lower airway. 360cc of sterile saline will be instilled into 2 sub-segments by instilling and aspirating 3 aliquots of 60cc sequentially into each sub-segment.~Venipuncture to obtain peripheral blood mononuclear cells (PBMCs) for the proposed assays.~Cells collected will be analyzed for various T-cell subsets and gene expression to help determine the type of immune response.

Intervention type: OTHER
Intervention: Bronchoscopy with lavage
Description: Bronchoscopy will be performed according to standard clinical procedures. Bronchoscopy will be performed under conscious sedation with continuous cardiopulmonary monitoring and the subject's upper airway will be anesthetized with topical lidocaine. The bronchoscope will be passed through the naris or mouth to the upper airway and then into the lower airway. 360cc of sterile saline will be instilled into 2 sub-segments by instilling and aspirating 3 aliquots of 60cc sequentially into each sub-segment.~Venipuncture to obtain peripheral blood mononuclear cells (PBMCs) for the proposed assays.~Cells collected will be analyzed for various T-cell subsets and gene expression to help determine the type of immune response.